Novavax Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 1994
Net Income	-545.06	-657.94	-1,743.75	-418.26	-132.69	Upgrade
Depreciation & Amortization	41.23	29.05	12.66	4.89	5.68	Upgrade
Share-Based Compensation	85.36	130.3	183.63	128.04	17.05	Upgrade
Other Operating Activities	-295.49	82.65	1,870	242.8	-26.65	Upgrade
Operating Cash Flow	-713.97	-415.94	322.95	-42.54	-136.62	Upgrade
Capital Expenditures	-58.81	-92.99	-57.49	-54.62	16.48	Upgrade
Acquisitions	0	0	0	-165.52	0	Upgrade
Change in Investments	0	0	157.64	-157.64	22.02	Upgrade
Investing Cash Flow	-58.81	-92.99	100.15	-377.78	38.49	Upgrade
Share Issuance / Repurchase	360.4	248.59	589.62	881.01	98.38	Upgrade
Debt Issued / Paid	-352.35	81.66	-127.91	-96.07	0	Upgrade
Other Financing Activities	-3.59	-5.26	-	199.82	-	Upgrade
Financing Cash Flow	4.47	324.99	461.71	984.76	98.38	Upgrade
Exchange Rate Effect	3.27	4.52	-5.29	2.12	-0.03	Upgrade
Net Cash Flow	-765.04	-179.41	879.52	566.56	0.22	Upgrade
Free Cash Flow	-772.77	-508.92	265.46	-97.16	-120.15	Upgrade
Free Cash Flow Margin	-78.56%	-25.68%	23.16%	-20.43%	-643.81%	Upgrade
Free Cash Flow Per Share	-7.67	-6.51	3.57	-1.69	-4.99	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).